Fibrosis regression following hepatitis C antiviral therapy  

作　　者：Aisha Elsharkawy Reham Samir Mohamed El-Kassas 

机构地区：[1]Department of Endemic Medicine and Hepatogastroenterology,Faculty of Medicine,Cairo University,Cairo 11566,Egypt [2]Department of Endemic Medicine,Faculty of Medicine,Helwan University,Cairo 11795,Egypt

出　　处：《World Journal of Hepatology》2022年第6期1120-1130,共11页世界肝病学杂志（英文版）（电子版）

摘　　要：Hepatitis C virus(HCV)infection is one of the most common causes of liver pathology.It is a major etiological factor of continuous liver injury by triggering an uncontrolled inflammatory response,causing liver fibrosis and cirrhosis.Liver fibrosis is a dynamic process that can be reversible upon timely cessation of the injurious agent,which in cases of HCV is represented by the sustained virological response(SVR)following antiviral therapies.Direct-acting antiviral therapy has recently revolutionized HCV therapy and minimized complications.Liver fibrosis can be assessed with variable invasive and non-invasive methods,with certain limitations.Despite the broad validation of the diagnostic and prognostic value of non-invasive modalities of assessment of liver fibrosis in patients with HCV,the proper interpretation of liver stiffness measurement in patients after SVR remains unclear.It is also still a debate whether this regression is caused by the resolution of liver injury following treatment of HCV,rather than true fibrosis regression.Regression of liver fibrosis can possess a positive impact on patient's quality of life reducing the incidence of complications.However,fibrosis regression does not abolish the risk of developing hepatocellular carcinoma,which mandates regular screening of patients with advanced fibrosis.

关 键 词：Fibrosis regression Hepatitis C virus Direct-acting antivirals Hepatocellular carcinoma Liver fibrosis CIRRHOSIS 

分 类 号：R512.63[医药卫生—内科学] R575.2[医药卫生—临床医学]